sotalol
FDA Approved
Description
Sotalol is a beta-blocker with additional Class III antiarrhythmic properties. It is used to treat and prevent ventricular arrhythmias including those associated with arrhythmogenic ventricular dysplasia. The drug prolongs cardiac action potential duration and refractory period.
Indications & Therapeutic Use
ventricular arrhythmias, atrial fibrillation, atrial flutter, arrhythmogenic ventricular dysplasia
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
sotalol
| Generic Name | sotalol |
| Brands | 1 brand available |
| Active Ingredient | sotalol hydrochloride |
| Drug Class | ventricular arrhythmias |
| Manufacturer | Bayer |
| Dosage Forms | oral tablet 80mg, 120mg, 160mg, 240mg; IV infusion 15mg/mL |
| Medical Code | C07AA07 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00000544 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes